Management of postmolar gestational trophoblastic disease with methotrexate and folinic acid: 15 years of experience.
OBJECTIVE
To study the incidence of postmolar gestational trophoblastic disease (GTD) following hydatidiform mole and to evaluate the effectiveness of single-agent chemotherapy using methotrexate with folinic acid rescue.


METHODS
A prospective study of all cases of hydatidiform mole diagnosed and treated in the department of obstetrics and gynecology, Medical College, Calicut, India, was started in June 1990 to determine the incidence of postmolar GTD and the effectiveness of single-agent chemotherapy with methotrexate and folinic acid in postmolar nonmetastatic GTD.


RESULTS
For the 15-year period from June 1990 to May 2005, 1,569 cases of hydatidiform mole were diagnosed and managed at our institution. The incidence of postmolar GTD among 1,569 cases of hydatidiform mole was 20.4%. Of the 321 cases of postmolar GTD diagnosed, 284 patients (88.5%) achieved complete remission with the methotrexate/folinic acid regimen. Fourteen multiparous patients (4.4%) underwent hysterectomy with methotrexate/folinic acid and achieved remission. Thus, 92.9% of patients with postmolar GTD had complete remission with the methotrexate/folinic acid regimen. The rest of the cases required multiagent therapy.


CONCLUSIONS
Regular follow-up of patients after evacuation of hydatidiform mole will detect cases of postmolar GTD at an early stage. Single-agent chemotherapy with methotrexate was effective in 92.9% of our cases.
Sekharan
P K
PK
Department of Obstetrics and Gynecology, Medical College, Calicut, India. drsekharanpk@hotmail.com
Sreedevi
N S
NS
Radhadevi
V P
VP
Beegam
Rasheeda
R
Raghavan
Jayandhi
J
Guhan
Beena
B
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D031901:Gestational Trophoblastic Disease / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000401:mortality / Q000473:pathology; D006801:Humans; D015994:Incidence; D007194:India / Q000453:epidemiology; D002955:Leucovorin / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D011247:Pregnancy; D011446:Prospective Studies; D011644:Puerperal Disorders / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000401:mortality; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000401:mortality
D002955:Leucovorin; D008727:Methotrexate